Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Consolidation With ADCT-402 (Loncastuximab Tesirine) After a Short Course of Immunochemotherapy: a Phase II Study in BTKi-treated (or BTKi Intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients

NCT05249959 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT05249959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05249959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Consolidation With ADCT-402 (Loncastuximab Tesirine) After a Short Course of Immunochemotherapy: a Phase II Study in BTKi-treated (or BTKi Intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 21, 2022
Completion date
March 31, 2029
Enrollment
49 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

refractory mantle cell lymphoma, relapsed mantle cell lymphoma